Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Immucell Corp /de/ ICCC US Equity

Health Care · CIK 811641 · FY ends Dec 31
$9.94
-0.08 (-0.80%)
USD · as of 2026-08-28 · marketstack

Immucell Corp /de/ (Nasdaq: ICCC), an SEC filer in In Vitro & In Vivo Diagnostic Substances, closed at $9.94, -0.8%, on 2026-08-28, with a market cap of $91M as of 2026-08-27, a return on equity of -3.8%, a net margin of -3.8% and 3-year sales growth of 14.2%. Institutional ownership, earnings history and filed financials are on the tabs below.

Short interest· FINRA consolidated · settlement 2026-08-14

6 settlement cycles
Shares short15K
% of shares out0.2%
Days to cover1.0
Δ vs 2026-07-31-13.5%
▲ 19K shares shortline top = 1.0d to cover2026-05-29: 9K short · 1.0d to cover2026-052026-06-15: 12K short · 1.0d to cover2026-062026-06-30: 19K short · 1.0d to cover2026-062026-07-15: 14K short · 1.0d to cover2026-072026-07-31: 18K short · 1.0d to cover2026-072026-08-14: 15K short · 1.0d to cover2026-08

bars = shares short · line = days to cover (own scale)

SettlementShares shortΔ vs priorAvg daily volumeDays to cover
2026-08-1415,224-13.5%29,7151.0
2026-07-3117,605+25.3%19,0091.0
2026-07-1514,048-24.9%41,6641.0
2026-06-3018,716+52.4%32,8061.0
2026-06-1512,281+35.1%17,6681.0
2026-05-299,088-12.9%44,2271.0

FINRA Rule 4560 · twice monthly, published ~a week later.

Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.